Traditional LNPs rely on passive targeting
-
Accumulates in the liver
Why It Matters
Many applications require cell or tissue specificity
-
Disease or cancer specific
Conjugation enables active targeting without redesigning the core formulation
Our services and capabilities
We offer end-to-end support for the development of targeted LNP systems, from conjugation strategy through formulation and characterization.​
​
-
Antibody–lipid conjugation (PEG-lipid linking, etc.)
-
Post insertion into pre-formed LNPs
-
Co-formulation approaches
-
Synthesis for mRNA, siRNA, and other payloads
-
Custom development based on target and indication
-
Analytical support
How It Works
1. Antibody selection and characterization​​
We evaluate and prepare the antibody for conjugation, including assessing purity, stability, and available functional groups to ensure compatibility with the chosen chemistry and downstream application.
​​​​​2. Conjugation to lipid anchor​​​​​​​​​​​​​​​​​​
We support a range of well-established and custom chemistries for conjugating antibodies to lipid anchors (typically PEG-lipids), depending on your molecule, desired orientation, and stability requirements, including:
​
Thiol-reactive
-
Maleimide–thiol (widely used for cysteine residues)​
​
Amine-reactive
-
NHS ester–amine (targets lysine residues)​
​
Click chemistry
-
DBCO–azide (copper-free click, very popular)
-
Azide–alkyne (CuAAC, copper-catalyzed)
3. Incorporation into LNP (formulation or post-insertion)​​​​
The antibody–lipid conjugate is incorporated into LNPs either during formulation or via post-insertion, depending on the desired surface density, workflow, and formulation constraints.
4. Characterization and validation
Final LNPs are characterized for size, PDI, encapsulation, and conjugation efficiency, with optional functional assays to confirm targeting and performance.
Request a Consultation
Contact
1460 Breda Drive Knoxville, TN 37918
1-800-491-1701
